Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy

This study has been terminated.
(Difficulty with enrollment)
Sponsor:
Collaborator:
CSL Behring
Information provided by (Responsible Party):
David M. Simpson, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier:
NCT01561755
First received: March 21, 2012
Last updated: September 14, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2016
  Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)